Tactile Systems: 3 Key Takeaways for Long-Term Investors

Tactile Systems raised full-year adjusted EBITDA guidance to $50-52 million, driven by 13% year-over-year growth in lymphedema product revenue to $81.8 million and operational improvements that reduced medical record review times by 50%. The company is absorbing temporary inventory delays in its airway clearance business through margin expansion and controlled spending, while positioning itself for sustained growth through expanded sales teams and AI-enabled order management systems.